335 related articles for article (PubMed ID: 18176600)
1. TLR7 and TLR8 as targets in cancer therapy.
Schön MP; Schön M
Oncogene; 2008 Jan; 27(2):190-9. PubMed ID: 18176600
[TBL] [Abstract][Full Text] [Related]
2. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion.
Schön MP; Schön M; Klotz KN
J Invest Dermatol; 2006 Jun; 126(6):1338-47. PubMed ID: 16575388
[TBL] [Abstract][Full Text] [Related]
3. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
Vasilakos JP; Tomai MA
Expert Rev Vaccines; 2013 Jul; 12(7):809-19. PubMed ID: 23885825
[TBL] [Abstract][Full Text] [Related]
4. The antitumoral mode of action of imiquimod and other imidazoquinolines.
Schön M; Schön MP
Curr Med Chem; 2007; 14(6):681-7. PubMed ID: 17346155
[TBL] [Abstract][Full Text] [Related]
5. [New perspective in immunotherapy: local imiquimod treatment].
Kemény L; Nagy N
Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
[TBL] [Abstract][Full Text] [Related]
6. Imiquimod: mode of action.
Schön MP; Schön M
Br J Dermatol; 2007 Dec; 157 Suppl 2():8-13. PubMed ID: 18067624
[TBL] [Abstract][Full Text] [Related]
7. TLR7/8 agonists trigger immunostimulatory properties of human 6-sulfo LacNAc dendritic cells.
Jähnisch H; Wehner R; Tunger A; Kunze A; Oehrl S; Schäkel K; Rohayem J; Bornhäuser M; Tonn T; Bachmann M; Schmitz M
Cancer Lett; 2013 Jul; 335(1):119-27. PubMed ID: 23402811
[TBL] [Abstract][Full Text] [Related]
8. Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod.
Schön MP; Schön M
Apoptosis; 2004 May; 9(3):291-8. PubMed ID: 15258460
[TBL] [Abstract][Full Text] [Related]
9. The TLR7/8 ligand resiquimod targets monocyte-derived dendritic cell differentiation via TLR8 and augments functional dendritic cell generation.
Hackstein H; Knoche A; Nockher A; Poeling J; Kubin T; Jurk M; Vollmer J; Bein G
Cell Immunol; 2011; 271(2):401-12. PubMed ID: 21889130
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the neuroinflammatory response to TLR7 stimulation in the brain: comparison of multiple TLR7 and/or TLR8 agonists.
Butchi NB; Pourciau S; Du M; Morgan TW; Peterson KE
J Immunol; 2008 Jun; 180(11):7604-12. PubMed ID: 18490763
[TBL] [Abstract][Full Text] [Related]
11. Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16.
Fahey LM; Raff AB; Da Silva DM; Kast WM
J Immunol; 2009 Mar; 182(5):2919-28. PubMed ID: 19234187
[TBL] [Abstract][Full Text] [Related]
12. TLRs to cytokines: mechanistic insights from the imiquimod mouse model of psoriasis.
Flutter B; Nestle FO
Eur J Immunol; 2013 Dec; 43(12):3138-46. PubMed ID: 24254490
[TBL] [Abstract][Full Text] [Related]
13. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
Hamm S; Rath S; Michel S; Baumgartner R
J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
[TBL] [Abstract][Full Text] [Related]
14. TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation.
Larangé A; Antonios D; Pallardy M; Kerdine-Römer S
J Leukoc Biol; 2009 Apr; 85(4):673-83. PubMed ID: 19164127
[TBL] [Abstract][Full Text] [Related]
15. Trial Watch: experimental TLR7/TLR8 agonists for oncological indications.
Frega G; Wu Q; Le Naour J; Vacchelli E; Galluzzi L; Kroemer G; Kepp O
Oncoimmunology; 2020 Jul; 9(1):1796002. PubMed ID: 32934889
[TBL] [Abstract][Full Text] [Related]
16. Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells.
Levy O; Suter EE; Miller RL; Wessels MR
Blood; 2006 Aug; 108(4):1284-90. PubMed ID: 16638933
[TBL] [Abstract][Full Text] [Related]
17. The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus.
Domingues R; de Carvalho GC; da Silva Oliveira LM; Futata Taniguchi E; Zimbres JM; Aoki V; da Silva Duarte AJ; Sato MN
Br J Dermatol; 2015 Jan; 172(1):48-55. PubMed ID: 24976336
[TBL] [Abstract][Full Text] [Related]
18. TLR7/8 agonists activate a mild immune response in rabbits through TLR8 but not TLR7.
Lai CY; Liu YL; Yu GY; Maa MC; Leu TH; Xu C; Luo Y; Xiang R; Chuang TH
Vaccine; 2014 Sep; 32(43):5593-9. PubMed ID: 25131730
[TBL] [Abstract][Full Text] [Related]
19. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptor 7 agonists and skin.
Novak N; Yu CF; Bieber T; Allam JP
Drug News Perspect; 2008 Apr; 21(3):158-65. PubMed ID: 18560614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
